III期非小细胞肺癌的真实世界治疗:免疫治疗时代三联模式的作用
该回顾性研究分析了2005年1月至2012年12月间638例接受根治性治疗的III期NSCLC患者,比较手术、放疗、放化疗及手术联合放疗的生存结局,并评估PACIFIC试验免疫治疗资格。结果显示手术与放化疗中位OS相似(28.6个月 vs 27.0个月),单纯放疗较差(17.5个月),手术联合放疗较优(55.8个月),但后者用于高度选择患者。
要点
- 638例III期NSCLC中,10%接受手术,15%放疗,64%放化疗,11%手术联合放疗。
- 中位OS:手术28.6个月,放化疗27.0个月,单纯放疗17.5个月,手术联合放疗55.8个月。
- 多因素模型中仅ECOG PS和治疗队列显著影响OS;病例匹配分析放化疗中位OS 31.9个月 vs 三联治疗55.8个月。
核心结论
- 在控制已知预后因素后,III期NSCLC患者接受手术与放化疗的生存表现相似。
- 单纯放疗与更差结局相关。
- 手术联合放疗似乎优于其他模式,但用于高度选择患者。
研究设计与样本
- 回顾性分析2005年1月至2012年12月间所有III期NSCLC患者,筛选接受根治性治疗者,收集已知预后和预测因素及PACIFIC试验免疫治疗资格信息,主要结局为总生存。
- 共638例III期NSCLC患者被转诊并接受根治性治疗:66例(10%)接受手术,95例(15%)接受放疗,410例(64%)接受放化疗,67例(11%)接受手术联合放疗。
主要发现
- 中位OS:手术28.6个月,放化疗27.0个月,单纯放疗17.5个月,手术联合放疗55.8个月。
- 多因素模型中仅ECOG PS和治疗队列显著影响OS。
- 病例匹配分析中,放化疗中位OS为31.9个月,三联治疗为55.8个月。
- 61%接受放化疗和88%接受三联治疗的患者可能符合辅助免疫治疗资格。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Curative intent treatment of stage III NSCLC is variable and influenced by both patient and disease characteristics. We performed a real-world analysis of curative therapies in stage III NSCLC, and explored the impact of known prognostic factors on outcome. METHODS: A retrospective review was completed of all patients with stage III NSCLC between January 2005 and December 2012. Cases were filtered to identify those receiving curative intent therapy including surgery, radiotherapy (RT), chemoradiotherapy (CRT), and combined modality with surgery (S + RT). Information was collected on known prognostic and predictive factors, and immunotherapy eligibility per the PACIFIC trial. The primary outcome measure was overall survival. RESULTS: A total of 638 patients with stage III NSCLC were referred and received curative intent treatment. Of these, 66 (10%) received surgery, 95 (15%) RT, 410 (64%) CRT, and 67 (11%) combined S + RT. Median overall survival (OS) was similar for surgery (28.6 mo) and CRT (27.0 mo), inferior for RT alone (17.5 mo), and superior for S + RT (55.8 mo). In a multivariate model only, Eastern Cooperative Oncology Group performance status (ECOG PS) and treatment cohort significantly influenced OS. In a case-matched analysis, the median OS for CRT was 31.9 months, compared to 55.8 months with trimodality treatment. Overall, 61% of patients receiving CRT and 88% of those receiving trimodality therapy would have been potentially eligible for adjuvant immunotherapy. CONCLUSIONS: In stage III NSCLC, the performance of surgery and CRT are similar after controlling for known prognostic factors. Radiotherapy alone is associated with worse outcomes. Combined S + RT appears to provide a significant benefit above other modalities, albeit in highly selected patients.
引用
- Moore S, Leung B, Wu J, et al. Real-World Treatment of Stage III NSCLC: The Role of Trimodality Treatment in the Era of Immunotherapy. J Thorac Oncol. 2019. PMID: 31002953. doi:10.1016/j.jtho.2019.04.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。